GH Research (NASDAQ:GHRS) Stock Price Up 2.8% – Still a Buy?

GH Research PLC (NASDAQ:GHRS) shares traded up 2.8% on Wednesday . The stock traded as high as $8.33 and last traded at $8.33. 3,888 shares traded hands during trading, a decline of 95% from the average session volume of 79,718 shares. The stock had previously closed at $8.10.

Analyst Ratings Changes

Several analysts have recently issued reports on GHRS shares. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of GH Research in a research note on Thursday, September 5th. JMP Securities reissued a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a research report on Wednesday, September 4th.

GH Research Stock Performance

The firm has a 50-day moving average price of $8.20 and a two-hundred day moving average price of $10.59. The firm has a market cap of $427.67 million, a price-to-earnings ratio of -12.13 and a beta of 0.79.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.03. Research analysts anticipate that GH Research PLC will post -0.89 earnings per share for the current year.

Institutional Investors Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP raised its position in GH Research PLC (NASDAQ:GHRS) by 80.1% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 3,310,563 shares of the company’s stock after buying an additional 1,471,946 shares during the quarter. GH Research comprises about 9.1% of Lynx1 Capital Management LP’s holdings, making the stock its 6th largest position. Lynx1 Capital Management LP owned approximately 6.36% of GH Research worth $35,291,000 at the end of the most recent reporting period. 56.90% of the stock is currently owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).